14 July 2016 - Companies continued to raise prices significantly in Q1.

Big pharma’s widespread habit of regularly raising the price of their medicines has galvanized public outrage and given 2016 political candidates a convenient piñata.

But new data suggest that, so far, the outrage is still more bark than bite.

More than two-thirds of the 20 biggest pharma companies used price hikes to drive revenue growth in the first quarter of 2016, according to an analysis of corporate filings and earnings statements by the Wall Street Journal. The review also found that drugmakers have been relying on this tactic more and more and raising prices by higher amounts than before despite multiple Congressional inquiries into the practice and proposed reforms to tackle drug costs from President Obama, Hillary Clinton, Donald Trump, and others.

View Forbes article